Literature DB >> 7769134

Association between maternal antibodies to the external envelope glycoprotein and vertical transmission of human T-lymphotropic virus type I. Maternal anti-env antibodies correlate with protection in non-breast-fed children.

S Hino1, S Katamine, T Miyamoto, H Doi, Y Tsuji, T Yamabe, J E Kaplan, D L Rudolph, R B Lal.   

Abstract

Vertical transmission of human T-lymphotropic virus type I (HTLV-I) depends primarily on breast-feeding; substitution of bottle-feeding has reduced the transmission rate from 20% in breast-fed children to 3% among bottle-fed. To determine the correlates of transmission for long breast-feeding (> or = 6 mo), short breast-feeding (< 6 mo), and bottle-feeding mothers, the antibody titers of transmitter (T) mothers and non-transmitter (nT) mothers were analyzed by using synthetic and recombinant epitopes representing the immunodominant epitopes of gag (Gag1a, r24), env (Env1/5, MTA1, RE3), and tax (Tax8/22-24) proteins. Seroreactivity to gag and tax epitopes was not significantly different except for anti-r24 antibody titer, which was significantly higher among T-mothers (geometric mean 134) when compared with nT-mothers (62) in the long-feeding group (P < 0.001). Profiles of antibody titers against env epitopes were different. Within the long-feeding group, Env1/5, MTA1, and RE3 titers were significantly higher among T-mothers (258, 1,476, and 738, respectively) when compared with nT-mothers (106, 279, and 320, respectively) (P < 0.01 for all three epitopes). In contrast, within the bottle-feeding group, antibody titers to Env1/5 (269) and RE3 (418) among nT-mothers were significantly higher than those among T-mothers (80 and 113, respectively) (P < 0.01). These data confirm that high-titered anti-HTLV-I antibodies in the long-feeding group correlate with milk-borne transmission of HTLV-I and, more importantly, imply that maternal anti-env antibodies may reduce the risk of non-milkborne infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7769134      PMCID: PMC295980          DOI: 10.1172/JCI117999

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  Immune responsiveness to the immunodominant recombinant envelope epitopes of human T lymphotropic virus types I and II in diverse geographic populations.

Authors:  C Buckner; C R Roberts; S K Foung; J Lipka; G R Reyes; K Hadlock; L Chan; R A Gongora-Biachi; B Hjelle; R B Lal
Journal:  J Infect Dis       Date:  1992-11       Impact factor: 5.226

2.  DNA amplification of human T lymphotropic virus type I (HTLV-I) proviral DNA in breast milk of HTLV-I carriers.

Authors:  M Nagamine; Y Nakashima; S Uemura; H Takei; T Toda; T Maehama; H Nakachi; M Nakayama
Journal:  J Infect Dis       Date:  1991-11       Impact factor: 5.226

3.  Evaluation of a recombinant human T-cell lymphotropic virus type I (HTLV-I) p21E antibody detection enzyme immunoassay as a supplementary test in HTLV-I/II antibody testing algorithms.

Authors:  T M Hartley; G E Malone; R F Khabbaz; R B Lal; J E Kaplan
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

4.  Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization.

Authors:  Y Tanaka; L Zeng; H Shiraki; H Shida; H Tozawa
Journal:  J Immunol       Date:  1991-07-01       Impact factor: 5.422

5.  Lymphocyte-facilitated infection of epithelia by human T-cell lymphotropic virus type I.

Authors:  V R Zacharopoulos; M E Perotti; D M Phillips
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

6.  Inhibitory effect of maternal antibody on mother-to-child transmission of human T-lymphotropic virus type I. The Mother-to-Child Transmission Study Group.

Authors:  K Takahashi; T Takezaki; T Oki; K Kawakami; S Yashiki; T Fujiyoshi; K Usuku; N Mueller; M Osame; K Miyata
Journal:  Int J Cancer       Date:  1991-11-11       Impact factor: 7.396

7.  Immunoglobulin prophylaxis against milkborne transmission of human T cell leukemia virus type I in rabbits.

Authors:  T Sawada; Y Iwahara; K Ishii; H Taguchi; H Hoshino; I Miyoshi
Journal:  J Infect Dis       Date:  1991-12       Impact factor: 5.226

8.  Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1.

Authors:  M Kuroki; M Nakamura; Y Itoyama; Y Tanaka; H Shiraki; E Baba; T Esaki; T Tatsumoto; S Nagafuchi; S Nakano
Journal:  J Immunol       Date:  1992-08-01       Impact factor: 5.422

9.  Complete nucleotide sequence of a highly divergent human T-cell leukemia (lymphotropic) virus type I (HTLV-I) variant from melanesia: genetic and phylogenetic relationship to HTLV-I strains from other geographical regions.

Authors:  A Gessain; E Boeri; R Yanagihara; R C Gallo; G Franchini
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

10.  Maternal transmission of HTLV-1 other than through breast milk: discrepancy between the polymerase chain reaction positivity of cord blood samples for HTLV-1 and the subsequent seropositivity of individuals.

Authors:  K Kawase; S Katamine; R Moriuchi; T Miyamoto; K Kubota; H Igarashi; H Doi; Y Tsuji; T Yamabe; S Hino
Journal:  Jpn J Cancer Res       Date:  1992-09
View more
  2 in total

1.  Seroprevalence and demographic determinants of human T-lymphotropic virus type 1 and 2 infections among first-time blood donors--United States, 2000-2009.

Authors:  Yun Brenda Chang; Zhanna Kaidarova; Daniel Hindes; Marjorie Bravo; Nancy Kiely; Hany Kamel; Denise Dubay; Barbara Hoose; Edward L Murphy
Journal:  J Infect Dis       Date:  2013-09-24       Impact factor: 5.226

2.  Intrahost variations in the envelope receptor-binding domain (RBD) of HTLV-1 and STLV-1 primary isolates.

Authors:  Felix J Kim; Madakasira Lavanya; Antoine Gessain; Sandra Gallego; Jean-Luc Battini; Marc Sitbon; Valérie Courgnaud
Journal:  Retrovirology       Date:  2006-05-25       Impact factor: 4.602

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.